Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA3 | P22001 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.30 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4386145 | 1.00 | KCNA3 (0.32) | KCNA3CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL4386141 | 1.00 | KCNA3 (0.32) | KCNA3CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL4389261 | 0.85 | — | — | |
| SCHEMBL4389264 | 0.85 | — | — | |
| SCHEMBL4389266 | 0.85 | — | — | |
| SCHEMBL4387645 | 0.84 | KCNA3 (0.36) | KCNA3 | |
| SCHEMBL4387778 | 0.84 | CHRM2 (0.31) | CHRM2CHRM3 | |
| SCHEMBL4387640 | 0.84 | KCNA3 (0.36) | KCNA3 | |
| SCHEMBL4387776 | 0.84 | CHRM2 (0.31) | CHRM2CHRM3 | |
| SCHEMBL4387775 | 0.84 | CHRM2 (0.31) | CHRM2CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306059-A1 | CYCLIC AMINE DERIVATIVE HAVING SUBSTITUTED ALKYL GROUP | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-12-10 | — | — | US | disclosed |
| EP-1889835-A1 | CYCLIC AMINE DERIVATIVE HAVING SUBSTITUTED ALKYL GROUP | Daiichi Sankyo Company, Limited (JP) | 2008-02-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306059-A1 | CYCLIC AMINE DERIVATIVE HAVING SUBSTITUTED ALKYL GROUP | CBR3, CNR1, C3AR1 | KCNA3 423/4885CHRM2 13/4885CHRM4 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.